Unlocking "unconventional" energy requires unconventional politics, and that's one resource that is genuinely scarce among today's backwards-looking bureaucrats and green interest groups.

U.S. House of Representatives hearing on tax policy impacts on the commercial application of renewable energy technology

The crisis in financing is having a chilling effect on biomedical innovation. As discussed in my last column, the main problem in our industry is that the sheer cost of drug development has become almost prohibitively expensive, effectively pricing almost everyone but the largest companies out of the market.

The general economic "health" of the U.S. manufacturing sector has re-emerged in a Presidential election year. In his 2012 State of the Union address, President Obama announced to Americans "that we have a huge opportunity, at this moment to bring manufacturing back," promising manufacturers special tax reductions and other federal...

As gasoline prices climb, President Obama's poll numbers plummet. In February, a Washington Post/ABC poll had Obama up 6 points against Mitt Romney. Monday's poll has him down 2. According to the polls, gas prices are a huge part of the story, particularly given how the last 30 days or so have not exactly been great for the GOP.

By next year, about two-thirds of American physicians will be working as salaried employees of large groups and hospitals. This movement has been underway for years. Over the last decade, the number of independent physicians was falling by about 2% a year. But these trends are now accelerating. 

Quick: How many kinds of gasoline do we use in America? Most people would say three or six: regular unleaded, mid-grade, and premium, along with the ethanol blends of the same that have become nearly universal. The actual number is somewhere above 45, though hard to pin down exactly, according...

By keeping the focus on better health for real people, perhaps we’ll develop both the humility to recognize how little we still understand as well as the drive to ensure — and emphatically demand — that our advances ultimately wind up not only in papers, but also in patients.